This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.

This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.

The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

The present disclosure provides a feed additive for domesticated animals that is capable of increasing feed performance, as well as associated methods for promoting growth and zootechnical performance in domesticated animals. The animal feed additive provided contains marrubiin, related compounds or biologically acceptable salts thereof, and in some embodiments Total Lignans standardized in the contents of Furoguaiacin-like compounds and Guaiacin-like compounds. The present disclosure also describes methods for improving growth via the dietary inclusion of marrubiin, related compounds or biologically acceptable salts thereof, and in certain embodiments Total Lignans standardized in Furoguaiacin-like compounds and Guaiacin-like compounds.

The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of the garcinia cambogia extract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.

Described herein are pet food compositions comprising from about 10 wt.% to about 50 wt.% protein; from about 10 wt.% to about 40 wt.% fat; up to about 20 wt.% fiber; and a moisture content of from about 6 wt.% to about 10 wt.%; wherein the weight percentages are based on the total weight of the pet food composition; wherein the pet food composition has a peak force of from about 5 kg to about 11 kg. Methods of making and using these compositions are also described herein.

Described herein are pet food compositions comprising from about 10 wt.% to about 50 wt.% protein; from about 10 wt.% to about 40 wt.% fat; up to about 20 wt.% fiber; and a moisture content of from about 6 wt.% to about 10 wt.%; wherein the weight percentages are based on the total weight of the pet food composition; wherein the pet food composition has a peak force of from about 5 kg to about 11 kg. Methods of making and using these compositions are also described herein.

A method for stabilizing a sanshool compound is provided. The method for stabilizing a sanshool compound comprises a mixing step in which the sanshool compound is mixed with an antioxidant in a liquid, the liquid comprising water and/or a water-soluble organic solvent and the mixing step being conducted under the conditions of a pH of 6 or higher.

A method for stabilizing a sanshool compound is provided. The method for stabilizing a sanshool compound comprises a mixing step in which the sanshool compound is mixed with an antioxidant in a liquid, the liquid comprising water and/or a water-soluble organic solvent and the mixing step being conducted under the conditions of a pH of 6 or higher.

The present invention relates to antiviral 1,2,4-trioxane compounds and compositions comprising the same that are effective inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication, and are thus useful to treat the coronavirus disease 2019 (COVID-19). The invention further provides pharmaceutical compositions containing such antiviral compounds and antiviral compositions, and methods of using these antiviral compounds, antiviral compositions and pharmaceutical compositions in the treatment and prevention of COVID-19.